Skip to main content
Fig. 2 | BMC Neurology

Fig. 2

From: Efficacy and safety of eptinezumab in patients with chronic migraine and medication-overuse headache: a randomized, double-blind, placebo-controlled study

Fig. 2

Change from baseline in mean MMDs (A) Weeks 1–12 and (B) 4-week intervals (FAS). The estimated means, mean differences from placebo, and 95% confidence intervals are from a mixed model for repeated measures with month (Weeks 1–4, Weeks 5–8, Weeks 9–12), region, stratification factor (monthly headache days at baseline: < 20/ ≥ 20), and treatment as factors, baseline score as a continuous covariate, treatment-by-month interaction, baseline score-by-month interaction, and stratum-by-month interaction. Data represent mean ± standard error. FAS, full analysis set; MMDs, monthly migraine days

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us